Natural Matrix Protein

Conditions

• Degenerative Lumbar Spinal Conditions

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Radiographic Evaluation — RADIATION
  surgical procedure

Study Details

This clinical study is a non-randomized, consecutive, single-center, retrospective-prospective investigation of patients who received NMP bioimplant (Induce Biologics, Tampa, FL) in lumbar spinal fusion procedures. The purpose of this study is to assess the radiographic, clinical, and safety outcomes of Natural Matrix Protein (NMP) as a graft alternative in lumbar fusion procedures. Utilizing the Hospital for Special Surgery's EPIC database under Institutional Review Board approval, all patients with symptomatic lumbar degenerative disc disease who failed conservative management at up to four vertebral levels between L1-S1 between February 2024 and December 2025 will be reviewed. The inclusion criteria for the study will be adult patients (≥ 18 years old) who underwent lumbar fusion with an NMP graft and interbody cage. The exclusion criteria will include previous lumbar fusion attempts, active malignancy, concurrently under chemotherapy, active infection at time of surgery, mentally compromised, and trauma to the operated region. It is expected approximately 100 patients will fit the inclusion/exclusion criteria. The objective of the study is to evaluate the clinical outcomes of the subjects treated with NMP

Key Dates

Start date

Mar 18, 2025

Status verified

Jun 2026

Primary completion

Mar 17, 2027

Completion

Sep 17, 2027

Study Design

Enrollment

100 participants (estimated)

Arms

• Arm: Adult patients (≥ 18 years old) who underwent lumbar fusion
  NMP graft with interbody cage

Primary Outcome Measure

Radiographs [ Time Frame: From May 2025 until May 2027 ]

Locations (1)

Find similar trials in New York, NY